Residence time distribution as a traceability method for lot changes in a pharmaceutical continuous manufacturing system

[Display omitted] Residence time distribution (RTD) models were developed to track raw material lots and investigate batch transitions in a continuous manufacturing system. Two raw materials with similar physical properties (granular metformin and lactose) were identified via Principal Component Ana...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutics Vol. 611; p. 121313
Main Authors Sánchez-Paternina, Adriluz, Martínez-Cartagena, Pedro, Li, Jingzhe, Scicolone, James, Singh, Ravendra, Lugo, Yleana C., Romañach, Rodolfo J, Muzzio, Fernando J., Román-Ospino, Andrés D.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 05.01.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] Residence time distribution (RTD) models were developed to track raw material lots and investigate batch transitions in a continuous manufacturing system. Two raw materials with similar physical properties (granular metformin and lactose) were identified via Principal Component Analysis (PCA) from a library of bulk material properties and used to simulate the switching of lots during production. In-line near-infrared (NIR) spectra were collected with the powder flowing through a chute in a continuous manufacturing system to monitor metformin and lactose concentration in step-change experiments with Partial Least Squares (PLS) models. RTD provided an understanding of raw material propagation through the continuous manufacturing system. Transition times between raw material changes were identified using the results of two multivariate approaches PLS and PCA. The methodology was implemented to discriminate the transition zone in a raw material change, contributing to design control strategies for acceptance and diverting mechanisms.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2021.121313